{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:32:50Z","timestamp":1778801570149,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ejps.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T17:19:16Z","timestamp":1431364756000},"page":"156-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Tanshinone IIA \u2013 loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation"],"prefix":"10.1016","volume":"76","author":[{"given":"Hong-Xiang","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2015.05.012_b0005","unstructured":"Administration, F.a.D., 1997. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations. Rockville, MD: Food and Drug Administration."},{"key":"10.1016\/j.ejps.2015.05.012_b0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2013.02.029","article-title":"Formulation of lipid bearing pellets as a delivery system for poorly soluble drugs","volume":"446","author":"Chopra","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2011.12.049","article-title":"Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro","volume":"424","author":"Chu","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejpb.2008.11.005","article-title":"Modulating pH-independent release from coated pellets: effect of coating composition on solubilization processes and drug release","volume":"72","author":"Ensslin","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.saa.2004.03.032","article-title":"Preparation and study on the inclusion complexes of two tanshinone compounds with \u03b2-cyclodextrin","volume":"61","author":"Fan","year":"2005","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejps.2015.05.012_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.041","article-title":"Cardiovascular actions and therapeutic potential of tanshinone IIA","volume":"220","author":"Gao","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejps.2015.05.012_b0035","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/jps.21220","article-title":"A comparison of the prediction accuracy of two IVIVC modelling techniques","volume":"97","author":"Gaynor","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-199120040-00001","article-title":"Noncompartmental versus compartmental modelling in clinical pharmacokinetics","volume":"20","author":"Gillespie","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2015.05.012_b0045","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1055\/s-2006-951698","article-title":"Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion","volume":"72","author":"Hao","year":"2006","journal-title":"Planta Med."},{"key":"10.1016\/j.ejps.2015.05.012_b0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138920007779816011","article-title":"Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation","volume":"8","author":"Hao","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2015.05.012_b0055","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.saa.2007.01.029","article-title":"Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging","volume":"68","author":"Huang","year":"2007","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejps.2015.05.012_b0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejps.2009.03.015","article-title":"Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form","volume":"37","author":"Jantratid","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ajps.2014.04.003","article-title":"Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit","volume":"9","author":"Kan","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0070","doi-asserted-by":"crossref","first-page":"151S","DOI":"10.1111\/j.1365-2125.1985.tb02756.x","article-title":"In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations","volume":"19","author":"Langenbucher","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2015.05.012_b0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/phrs.1996.0016","article-title":"The clinical relevance of chronopharmacology in therapeutics","volume":"33","author":"Lemmer","year":"1996","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2015.05.012_b0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pharmthera.2005.11.008","article-title":"The importance of circadian rhythms on drug response in hypertension and coronary heart disease\u2014from mice and man","volume":"111","author":"Lemmer","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2015.05.012_b0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2005.07.048","article-title":"Simultaneous determination of tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography-electrospray ionisation-mass spectrometry","volume":"826","author":"Li","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2015.05.012_b0090","first-page":"1724","article-title":"Study on the solubility and permeability of tanshinone II A and on the excipients increasing the solubility and permeability","volume":"19","author":"Li","year":"2008","journal-title":"Lishizhen Med. Mater Med. Res."},{"key":"10.1016\/j.ejps.2015.05.012_b0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejpb.2011.11.003","article-title":"Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation","volume":"80","author":"Li","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0100","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/jps.23199","article-title":"Release behavior of tanshinone IIA sustained-release pellets based on crack formation theory","volume":"101","author":"Liu","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0105","unstructured":"Meyer, K., Kolter, K., 2004. Reliability of drug release from an innovative single unit Kollicoat\u00ae drug delivery system, CRS 2004. In: 31st International Symposium on Controlled Release of Bioactive Materials."},{"key":"10.1016\/j.ejps.2015.05.012_b0110","unstructured":"Mies, S., Meyer, K., Kolter, K., 2004. Correlation of drug permeation through isolated films and coated dosage forms based on Kollicoat\u00ae SR 30D\/IR. iN: 2004 AAPS Annual Meeting and Exposition."},{"key":"10.1016\/j.ejps.2015.05.012_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0753-3322(02)00313-X","article-title":"Circadian variation of basal total vascular tone and chronotherapy in patients with vasospastic angina pectoris","volume":"56","author":"Mori","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2015.05.012_b0120","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.addr.2006.07.029","article-title":"Chronobiology and chronotherapy of ischemic heart disease","volume":"59","author":"Portaluppi","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.05.012_b0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(59)90003-8","article-title":"Angina pectoris I. A variant form of angina pectoris: preliminary report","volume":"27","author":"Prinzmetal","year":"1959","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2015.05.012_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0378-5173(03)00184-4","article-title":"Convolution method to predict drug concentration profiles of 2, 3, 5, 6-tetramethylpyrazine following transdermal application","volume":"259","author":"Qi","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0135","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/716459","article-title":"Tanshinone IIA: a promising natural cardioprotective agent","author":"Shang","year":"2012","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.ejps.2015.05.012_b0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0939-6411(01)00248-X","article-title":"The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets","volume":"53","author":"Sirisuth","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2015.05.012_b0145","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0002-8703(99)70392-3","article-title":"Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease","volume":"137","author":"Smolensky","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejps.2015.05.012_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejps.2004.11.007","article-title":"In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media","volume":"24","author":"Sunesen","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0155","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jps.2600670524","article-title":"Mathematical basis of point-area deconvolution method for determining in vivo input functions","volume":"67","author":"Vaughan","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.05.012_b0160","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1023\/A:1012252822432","article-title":"An extended point-area deconvolution approach for assessing drug input rates","volume":"18","author":"Yeh","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.05.012_b0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/02652040701852181","article-title":"Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: Influence of Poloxamer 188 coating on phagocytic uptake","volume":"25","author":"Zhang","year":"2008","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2015.05.012_b0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biomaterials.2012.09.058","article-title":"Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2015.05.012_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2008.01.004","article-title":"Evaluation of in vivo\u2013in vitro release of dexamethasone from PLGA microspheres","volume":"127","author":"Zolnik","year":"2008","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T06:12:41Z","timestamp":1589523161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098715002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"alternative-id":["S0928098715002080"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2015.05.012","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tanshinone IIA \u2013 loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}